Sun Pharmaceutical Industries Ltd on Tuesday announced the launch of Favipiravir, under brand name FluGuard, at Rs 35 per tablet for the treatment of mild to moderate cases of Covid-19 in India.

Favipiravir is an oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

The stocks of FluGuard will be available in the market from this week, Sun Pharma said.

“With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals.”

“We are launching FluGuard at an economical price to make the drug accessible to more and more patients, thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response.”
Kirti Ganorkar, CEO of India Business, Sun Pharma

Sun Pharma said it will work closely with the government and the medical community to ensure availability of FluGuard to patients across the country.

Several other companies have launched the generic versions of Favipiravir so far in India.

Last week, Hetero, announced the launch of generic Favipiravir in India under the brand name Favivir at Rs 59 per tablet.

Earlier, Cipla announced the launch of Favipiravir in the country under the brand name Ciplenza at Rs 68 per tablet.

Glenmark Pharmaceuticals made its Favipiravir drug available under the brand name FabiFlu at Rs 75 per tablet.

(This story was published from a syndicated feed. Only the headline and picture has been edited by FIT)

(At The Quint, we question everything. Play an active role in shaping our journalism by becoming a member today.)

Become a Member to unlock
  • Access to all paywalled content on site
  • Ad-free experience across The Quint
  • Early previews of our Special Projects
Continue

Published: undefined

ADVERTISEMENT
SCROLL FOR NEXT